

Department of Medicine Presents
The Dawn Hall Memorial Lecture for
Medicine Grand Rounds

Elizabeth M. Gaughan & William W. Grosh, MD
Division of HemeOnc
University of Virginia, School of Medicine

Immunotherapy Management of Advanced Malignancy:
New Potential and New Toxicity

Wednesday, July 6th, 2016

12:00 – 1:00pm

Old Jordan Auditorium 1-5

Disclosures:

Speaker: Elizabeth M. Gaughan, MD, is an Industry sponsored research/investigator for Bristol-Myers-Squibb.

William Grosh, MD, Does Consultative services for NeoHealth & Prometheus.

Planning Committee: Gerald Donowitz, MD, Ross Buerlein, MD, Peter Liu, MD, Erin McLoughlin, MD, and Annie Smith, MD; do not have any personal or professional financial relationships with commercial entities producing healthcare goods and/or services.

Learning Objectives

- 1) Define mechanisms of action, indications and response patterns for checkpoint inhibitor therapy
- 2) Recognize immune related adverse events
- 3) Understand initial steps in management of immune related toxicity and role of specialty care.

The University Of Virginia School Of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University Of Virginia School Of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University Of Virginia School Of Medicine awards 1.0 hours of participation (equivalent to AMA PRA Category 1 Credit™) to each non-physician participant who successfully completes this educational activity. The University Of Virginia School Of Medicine maintains a record of participation for six (6) years.